Sight Sciences (NASDAQ:SGHT – Get Free Report) and Integra LifeSciences (NASDAQ:IART – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.
Earnings & Valuation
This table compares Sight Sciences and Integra LifeSciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sight Sciences | $79.55 million | 3.44 | -$38.43 million | ($0.71) | -7.08 |
| Integra LifeSciences | $1.64 billion | 0.91 | -$516.47 million | ($6.46) | -2.98 |
Risk & Volatility
Sight Sciences has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500. Comparatively, Integra LifeSciences has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500.
Insider & Institutional Ownership
55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 84.8% of Integra LifeSciences shares are owned by institutional investors. 30.4% of Sight Sciences shares are owned by insiders. Comparatively, 3.8% of Integra LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Sight Sciences and Integra LifeSciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sight Sciences | 1 | 3 | 5 | 0 | 2.44 |
| Integra LifeSciences | 2 | 4 | 1 | 0 | 1.86 |
Sight Sciences presently has a consensus target price of $8.25, suggesting a potential upside of 64.02%. Integra LifeSciences has a consensus target price of $18.33, suggesting a potential downside of 4.76%. Given Sight Sciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Sight Sciences is more favorable than Integra LifeSciences.
Profitability
This table compares Sight Sciences and Integra LifeSciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sight Sciences | -46.83% | -52.34% | -28.49% |
| Integra LifeSciences | -30.15% | 17.42% | 5.00% |
Summary
Sight Sciences beats Integra LifeSciences on 8 of the 14 factors compared between the two stocks.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
About Integra LifeSciences
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
